NasdaqGS:ZVRAPharmaceuticals
Zevra Therapeutics (ZVRA) Profit Swing To US$77.6m TTM Tests Rare Disease Bull Case
Zevra Therapeutics (ZVRA) has wrapped up FY 2025 with Q4 total revenue of US$34.1 million and basic EPS of US$0.21, while trailing twelve month figures show total revenue of US$106.5 million and basic EPS of US$1.40. Over the past year, the company has seen total revenue move from US$23.6 million on a trailing basis in Q4 2024 to US$106.5 million by Q4 2025, alongside a shift from a trailing net loss of US$105.5 million to trailing net income of US$77.6 million. This sets the stage for a more...